195 related articles for article (PubMed ID: 155195)
1. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
Tolosa ES
Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
[No Abstract] [Full Text] [Related]
2. The endocrinology of extrapyramidal system disorders.
Kirkpatrick B; Tamminga CA
Endocrinol Metab Clin North Am; 1988 Mar; 17(1):159-72. PubMed ID: 2967753
[TBL] [Abstract][Full Text] [Related]
3. Clozapine therapy for Parkinson's disease and other movement disorders.
Pfeiffer C; Wagner ML
Am J Hosp Pharm; 1994 Dec; 51(24):3047-53. PubMed ID: 7856623
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Bezard E; Brotchie JM; Gross CE
Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
[TBL] [Abstract][Full Text] [Related]
5. Choline chloride in the treatment of Huntington's disease and tardive dyskinesia: a preliminary report.
Davis KL; Berger PA; Hollister LE; Simonton SC
Psychopharmacol Bull; 1977 Jul; 13(3):37-8. PubMed ID: 142261
[No Abstract] [Full Text] [Related]
6. Drug holiday in Huntington's disease.
Schmidt EZ; Hofmann P; Kapfhammer HP; Bonelli RM
Ann Pharmacother; 2005 Apr; 39(4):773. PubMed ID: 15741414
[No Abstract] [Full Text] [Related]
7. The endocrinology of extrapyramidal system disorders.
Kirkpatrick B; Tamminga CA
Neurol Clin; 1988 Feb; 6(1):159-72. PubMed ID: 2967909
[TBL] [Abstract][Full Text] [Related]
8. GABA and movement disorders.
Marsden CD; Sheehy MP
Adv Biochem Psychopharmacol; 1981; 30():225-34. PubMed ID: 6460427
[No Abstract] [Full Text] [Related]
9. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
10. Oculomotor abnormalities in diseases of the basal ganglia.
Kennard C; Lueck CJ
Rev Neurol (Paris); 1989; 145(8-9):587-95. PubMed ID: 2530611
[TBL] [Abstract][Full Text] [Related]
11. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Fenney A; Jog MS; Duval C
Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
[TBL] [Abstract][Full Text] [Related]
12. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
Walters AS; McHale D; Sage JI; Hening WA; Bergen M
Clin Neuropharmacol; 1990 Jun; 13(3):236-40. PubMed ID: 2141544
[TBL] [Abstract][Full Text] [Related]
13. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
[TBL] [Abstract][Full Text] [Related]
14. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
[No Abstract] [Full Text] [Related]
15. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
Stahl SM; Davis KL; Berger PA
J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in Parkinson's disease and Huntington's chorea.
Barbeau A
Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
[No Abstract] [Full Text] [Related]
18. The emerging role of clozapine in the treatment of movement disorders.
Factor SA; Friedman JH
Mov Disord; 1997 Jul; 12(4):483-96. PubMed ID: 9251065
[TBL] [Abstract][Full Text] [Related]
19. [Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
Destee A
LARC Med; 1984 Feb; 4(2):107-11. PubMed ID: 6232436
[No Abstract] [Full Text] [Related]
20. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
